Business Context and Reporting Period
Company: DNA X, Inc. (formerly Sonim Technologies, Inc.)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: The Company has pivoted from manufacturing rugged cell phones and mobile hotspots to operating an AI and cryptocurrency trading platform (DNA X). On January 23, 2026, the Company sold substantially all assets of its legacy hardware business to Pace Car Acquisition LLC. The legacy operations are reported as discontinued operations. The Company is currently developing and testing enhancements to its DNA X trading platform, which is not yet open to the general public.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Net Revenues (Continuing) | $0 | $0 |
| Net Income (Loss) | $5,093 | $(7,017) |
| Net Loss from Continuing Operations | $(5,166) | $(2,821) |
| Income from Discontinued Operations | $10,259 | $(4,196) |
| Cash and Cash Equivalents (End of Period) | $900 | $2,006 |
| Total Assets | $4,517 | $43,898 |
| Total Liabilities | $5,749 | $50,625 |
| Stockholders' Deficit | $(1,232) | $(7,955) |
Note: All share and per-share amounts have been retroactively adjusted for a 1-for-18 reverse stock split effective October 28, 2025.
Material Changes vs. Prior Period
- Asset Sale and Discontinued Operations: The primary driver of the $5.1 million net income for the six months ended June 30, 2026, was a $15.3 million pre-tax gain on the sale of the legacy phone and hotspot business (classified as discontinued operations). In contrast, the prior year period included operating losses from this business.
- Continuing Operations Loss: Continuing operations incurred a net loss of $5.2 million for the six months ended June 30, 2026, compared to $2.8 million in the prior year. This increase is attributed to higher General and Administrative expenses ($4.9 million vs. $2.3 million), driven by $1.9 million in severance costs related to the asset sale and executive compensation reclassifications.
- Balance Sheet Transformation: Total assets decreased significantly from $43.9 million to $4.5 million due to the divestiture of the hardware business. Total liabilities decreased from $50.6 million to $5.7 million as legacy debts were settled or assumed by the buyer.
- Debt Restructuring: The Company extinguished a $1.2 million note and issued a new $3.1 million convertible note to DNA Holdings in May 2026, recognizing a $191,000 gain on extinguishment. This new note was subsequently converted to preferred stock in July 2026 (subsequent event).
Guidance, Outlook, and Risks
- Liquidity and Capital Resources: As of June 30, 2026, the Company held $900,000 in cash. However, subsequent to the reporting period (July and August 2026), the Company raised $5.0 million in cash through the sale of Series B Convertible Preferred Stock to DNA Holdings. Management believes this capital is sufficient to fund operations and platform enhancements for at least 12 months.
- Outlook: The Company plans to re-launch the DNA X trading platform in the fourth quarter of 2026. Revenue is currently $0 as the platform is closed for development. The Company expects to generate commission revenue upon relaunch.
- Material Weakness in Internal Controls: The Company identified a material weakness in internal control over financial reporting due to a lack of personnel with sufficient technical accounting expertise to handle complex transactions (specifically regarding investments and acquisitions). This weakness remains unresolved as of June 30, 2026.
- Risks: Key risks include the ability to attract customers to the new platform, volatility in cryptocurrency markets, reliance on third-party contractors for software development, and the need to maintain Nasdaq listing compliance.
Investor Verification Checklist
- Revenue Recognition: Verify the timeline for the relaunch of the DNA X platform and the specific conditions required to generate commission revenue, as current revenue is $0.
- Subsequent Financing: Confirm the terms and conversion mechanics of the $5.0 million Series B Preferred Stock issued to DNA Holdings in July and August 2026.
- Internal Controls: Assess the remediation plan for the material weakness in internal controls regarding complex accounting transactions.
- Related Party Transactions: Review the concentration of ownership and influence held by DNA Holdings (approx. 15% of outstanding stock) and the terms of the convertible notes and preferred stock issued to them.
- Asset Sale Receivable: Monitor the collection of the $1.248 million receivable held back from the asset sale, which is subject to indemnity claims.